Latest News

Thursday, November 15, 2018

Migraines that Affect Vision May Increase Risk of Atrial Fibrillation

People who experience migraine with visual aura may have an increased risk of atrial fibrillation (AFib), according to a study published in Neurology.  Participants in thelongitudinal, co…

Read the full story

Wednesday, November 14, 2018

Study Confirms Benefits of Laser Interstitial Thermal Therapy

A prospective, multi-center clinical study of 42 patients with brain lesions that recurred after stereotactic radiosurgery (SRS) for metastatic brain tumors showed positive outcomes for lase…

Read the full story

Tuesday, November 13, 2018

Possible Therapy for Polio-Like Illness Is Not Effective

In new research on a potential treatment for acute flaccid myelitis, the antidepressant fluoxetine showed no efficacy. The study, published in the November 9, 2018 online issue of Neurology, …

Read the full story

Wednesday, November 07, 2018

Another Beta-Secretase 1 (BACE) Inhibitor Phase 3 Trial Stopped

A trial of investigational drugs LY3202626 and LY3002813 (also known as N3pG mAB) (BACE IV; Eli Lilly, Indianapolis, IN) in combination for patients with Alzheimer’s disease (AD) has been termin…

Read the full story

Tuesday, November 06, 2018

Neurostimulation-Enabled Prosthetic Hand Delivers Sensory Input

In a first-in-human trial of the neural-enabled prosthetic hand (NEPH) system, promising results have been announced by the Florida Interenational University, investigator Ranu Jung, and the Adaptive …

Read the full story

Monday, November 05, 2018

Clobazam Oral Film Approved For Treatment of Lennox-Gastaut Syndrome

The Food and Drug Administration (FDA) has approved an oral film clobazam (Sympazan; Aquestive Therapeutics, Warren, NJ) for the adjunctive treatment of seizures in patients, age 2 years and up, with …

Read the full story

Friday, November 02, 2018

Effect of Pimavanserin for Parkinson’s Disease Psychosis Found Larger in Patients with Impaired Cognition

A post hoc analysis of data from the 6‐week phase 3 trial (NCT01174004) of pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) in patients with Parkinson’s disease psychosis (PDP) h…

Read the full story

Thursday, November 01, 2018

Epidiolex for Dravet Syndrome and Lennox Gastaut Syndrome Available for Prescription

Pharmaceutical grade cannabidiol (CBD) (Epidiolex; Greenwich Biosciences, Carlsbad, CA), approved by the FDA for treatment of patients age 2 and up with Lennox-Gastaut Syndrome (LGS) and Dravet Syndro…

Read the full story

Tuesday, October 30, 2018

Positive Top-Line Results Announced from Phase 2 Study of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

Pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA), already approved for treatment of patients with Parkinson’s disease (PD) psychosis is also being studied as a potential adjunctive…

Read the full story

Monday, October 29, 2018

Evidence Growing That Eyes May Be A Window to Alzheimer’s Diagnosis

Results presented at the 122ndAnnual Meeting of the American Academy of Ophthalmology suggest that optical coherence tomography (OCT) and OCT-angiography (OCTA) may be diagnostic for patients with pre…

Read the full story

Wednesday, October 24, 2018

Correlation of Higher Cortisol Levels, Cognitive Deficits, and Lower Brain Volume Varies by Sex

In a study published in today’s issue of Neurology, data from participants in the Framingham Heart study (generation 3) identified a correlation among high blood cortisol levels (> 15.8 …

Read the full story

Wednesday, October 24, 2018

Personal Pain Management App Approved for Use with Intrathecal Drug Delivery Pump

The US Food and Drug Administration (FDA) has approved use of an application (myPTM Personal Therapy Manager; Medtronic, Dublin, Ireland) for patients with chronic pain to use on a touchscreen device …

Read the full story

Wednesday, October 24, 2018

Positive Preliminary Phase 2 Clinical Trial Results for Bryostatin as Treatment for Alzheimer’s Disease

At the 11thEdition of Clinical Trials on Alzheimer’s Disease (CTAD) interim results were shared from a phase 2 trial (NCT03560245) evaluating the use of bryostatin (Neurotrope, Princeton, NJ) fo…

Read the full story

Tuesday, October 23, 2018

New Data Available on Risk of Relapse During Pregnancy for Women With Multiple Sclerosis

Multiple sclerosis (MS) most often affects women of childbearing age, making family planning and management of the disease before, during, and after pregnancy a primary concern for many patients. In 2…

Read the full story

Tuesday, October 23, 2018

First Patient Treated in Trial of BHV-3500—A Nasally Delivered CGRP-Receptor Antagonist Being Investigated for Migraine

The first participant has been treated in a clinical trial of BHV-3500 (Biohaven, New Haven, CT) for the treatment of patients with migraine. The first intranasal formulation of a calcitonin gene-rela…

Read the full story
Load More